LivaNova PLC
NASDAQ:LIVN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
43.38
64.15
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
LivaNova PLC
LivaNova PLC
Cash & Cash Equivalents
LivaNova PLC
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
LivaNova PLC
NASDAQ:LIVN
|
Cash & Cash Equivalents
$346.4m
|
CAGR 3-Years
24%
|
CAGR 5-Years
36%
|
CAGR 10-Years
11%
|
|
|
Smith & Nephew PLC
LSE:SN
|
Cash & Cash Equivalents
$568m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
EKF Diagnostics Holdings PLC
LSE:EKF
|
Cash & Cash Equivalents
£9.8m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-1%
|
|
|
Angle PLC
LSE:AGL
|
Cash & Cash Equivalents
£17.9m
|
CAGR 3-Years
24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Creo Medical Group PLC
LSE:CREO
|
Cash & Cash Equivalents
£9.8m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
B
|
Belluscura PLC
LSE:BELL
|
Cash & Cash Equivalents
$2m
|
CAGR 3-Years
58%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
LivaNova PLC
Glance View
LivaNova PLC is a dynamic player in the realm of medical technology, with its roots tracing back to the merger of two well-established entities, Sorin Group and Cyberonics, in 2015. This union was more than just a blending of operations; it marked the convergence of expertise in cardiac surgery and neuromodulation. Headquartered in London, LivaNova set out with a mission to innovate within the treatment space for life-critical conditions, making a name for itself in the healthcare sector by focusing on two principal areas: cardiovascular solutions and neuromodulation therapy. These areas aren't just buzzwords; they represent the backbone of the company’s operations, serving critical patient needs with a near-requirement for continuous technological advancement. LivaNova's revenue streams are primarily derived from its cutting-edge products used in life-sustaining procedures and therapeutic interventions. In cardiovascular solutions, the company excels with its offerings in heart-lung machines, used in cardiac surgeries, and heart valves, instrumental in treating heart valve disease. Meanwhile, their neuromodulation division stands at the forefront of treating refractory epilepsy and depression with devices that deliver electrical impulses to the vagus nerve. By continuously pushing the envelope on medical tech, LivaNova not only ensures reliable outcomes for patients but also maintains a robust portfolio that draws revenues from hospitals and clinics worldwide. This balance of innovative prowess and strategic product deployment is what enables LivaNova to mitigate risks and sustain its financial health amidst the volatile landscape of the global healthcare market.
See Also
What is LivaNova PLC's Cash & Cash Equivalents?
Cash & Cash Equivalents
346.4m
USD
Based on the financial report for Sep 30, 2024, LivaNova PLC's Cash & Cash Equivalents amounts to 346.4m USD.
What is LivaNova PLC's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
11%
Over the last year, the Cash & Cash Equivalents growth was 48%. The average annual Cash & Cash Equivalents growth rates for LivaNova PLC have been 24% over the past three years , 36% over the past five years , and 11% over the past ten years .
You don't have any saved screeners yet